CN115210256A - 用于前列腺癌诊断的新方法和化合物 - Google Patents

用于前列腺癌诊断的新方法和化合物 Download PDF

Info

Publication number
CN115210256A
CN115210256A CN202180017928.9A CN202180017928A CN115210256A CN 115210256 A CN115210256 A CN 115210256A CN 202180017928 A CN202180017928 A CN 202180017928A CN 115210256 A CN115210256 A CN 115210256A
Authority
CN
China
Prior art keywords
leu
ser
seq
gly
cdr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180017928.9A
Other languages
English (en)
Chinese (zh)
Inventor
安德斯·瓦尔登斯特伦
安德斯·拉松
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Swedish Plow Medical Ltd
Original Assignee
Swedish Plow Medical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Swedish Plow Medical Ltd filed Critical Swedish Plow Medical Ltd
Publication of CN115210256A publication Critical patent/CN115210256A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202180017928.9A 2020-03-03 2021-03-01 用于前列腺癌诊断的新方法和化合物 Pending CN115210256A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20160712.4 2020-03-03
EP20160712.4A EP3875482A1 (en) 2020-03-03 2020-03-03 New method and compound for prostate cancer diagnosis
PCT/EP2021/055061 WO2021175788A1 (en) 2020-03-03 2021-03-01 New method and compound for prostate cancer diagnosis

Publications (1)

Publication Number Publication Date
CN115210256A true CN115210256A (zh) 2022-10-18

Family

ID=69770502

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180017928.9A Pending CN115210256A (zh) 2020-03-03 2021-03-01 用于前列腺癌诊断的新方法和化合物

Country Status (7)

Country Link
US (1) US20230093265A1 (https=)
EP (2) EP3875482A1 (https=)
JP (1) JP7827630B2 (https=)
CN (1) CN115210256A (https=)
AU (1) AU2021232524A1 (https=)
CA (1) CA3168158A1 (https=)
WO (1) WO2021175788A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI131968B1 (en) * 2023-10-16 2026-03-17 Teknologian Tutkimuskeskus Vtt Oy ANTIBODY BINDINGS AS CANCER BIOMARKERS

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU9374198A (en) * 1997-09-08 1999-03-29 Idec Pharmaceuticals Corporation Methods for producing human antibodies in scid mice using dendritic cells
SE535084C2 (sv) * 2010-04-16 2012-04-10 Prostasom Handelsbolag Förfarande för cancerdiagnos
US9029086B2 (en) * 2012-01-26 2015-05-12 Masood Kamali Moghaddam Detection of single and multimodal analytes

Also Published As

Publication number Publication date
US20230093265A1 (en) 2023-03-23
EP3875482A1 (en) 2021-09-08
WO2021175788A1 (en) 2021-09-10
JP7827630B2 (ja) 2026-03-10
AU2021232524A1 (en) 2022-09-29
EP4114853A1 (en) 2023-01-11
CA3168158A1 (en) 2021-09-10
JP2023516705A (ja) 2023-04-20

Similar Documents

Publication Publication Date Title
CN102971343B (zh) 用于癌症诊断和/或预后的新型抗体
JP6324970B2 (ja) 抗ウロプラキンｉｉ抗体システムおよび方法
CN103827144B (zh) 新的抗cxcr4抗体及其用于检测和诊断癌症的用途
EP3094976B1 (en) Cell surface prostate cancer antigen for diagnosis
KR102317805B1 (ko) 전립선암을 검출하기 위한 조성물 및 방법
KR102795552B1 (ko) 트립토파닐-티알엔에이 합성효소 단백질에 특이적으로 결합하는 항체 및 이의 용도
CN108700586A (zh) 用于评估癌症发生的风险的组合物和方法
CN115210256A (zh) 用于前列腺癌诊断的新方法和化合物
JPWO2018135653A1 (ja) 抗ｅｐｈａ２抗体及びこれを用いたｅｐｈａ２の免疫学的検出
CN107709362B (zh) Igf-1r抗体及其用于癌症诊断的用途
CN115335408B (zh) 特异性结合wrs蛋白的抗体及其用途
CN110596369A (zh) 一种用于检测人tim-3表达水平的试剂盒
TWI869740B (zh) 一種體外檢測ｓＴＮＦＲ２蛋白濃度的方法及其檢測試劑和檢測試劑盒
KR20160093502A (ko) 항 eprs 모노클로날 항체 및 이의 용도
HK1248730B (zh) Igf-1r抗体及其用於癌症诊断的用途
HK1243434B (zh) Igf-1r抗体及其诊断癌症的用途
HK1225791B (en) Cell surface prostate cancer antigen for diagnosis
HK1262633B (zh) 用於评估癌症发生的风险的组合物和方法
CN108727493A (zh) 抗Stathmin单克隆抗体及其用途
HK1183311A (en) Novel antibody for the diagnosis and/or prognosis of cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination